Close

Form 6-K Cardiol Therapeutics For: Oct 03

October 3, 2022 8:08 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2022

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[  ] Form 20-F  [    x   ] Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [          ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [          ]


SUBMITTED HEREWITH

Exhibits

Exhibit   Description
   
99.1   News Release dated October 3, 2022 -  Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx™ Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

CARDIOL THERAPEUTICS INC.

 

(Registrant)

 

 

 

Date: October 3, 2022

By:

/s/ Chris Waddick

 

 


 

 

Chris Waddick

 

Title:

Chief Financial Officer



ATTACHMENTS / EXHIBITS

EXHIBIT 99.1



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings